The latest headlines and interview extracts:

Analyst recommends AVI BioPharma (8/28/03)
- RENI BENJAMIN, PHD, Rodman and Renshaw
- Biotechnology

Analyst says Geron has cancer vaccine data coming up that could move the stock significantly (8/28/03)
- RENI BENJAMIN, PHD, Rodman and Renshaw
- Biotechnology

CEO of Alltracel Pharmaceuticals discusses strategy and opportunities for stops-bleeding products in wound care market (6/3/03)
- GERARD BRANDON, Alltracel Pharmaceuticals
- Pharmaceuticals

CEO of Pharming Group discusses progress of lead product for hereditary angioedema (6/3/03)
- FRANCIS PINTO, Pharming Group
- Biotechnology

CE of Oxford BioMedica discusses progress of two lead cancer products (5/7/03)
- ALAN KINGSMAN, Oxford BioMedica PLC
- Biotechnology

CEO of Provalis plc says diabetes diagnostic product, Glycosal, has done extremely well in the States during first six months (5/7/03)
- PHIL GOULD, Provalis plc
- Biotechnology

President & CEO of Compugen Ltd. talks about potential long-term large revenues from licensing of in-house discoveries (5/1/03)
- DR. MOR AMITAI, Compugen Ltd.
- Biotechnology

Executive Chairman and Deputy Chairman of Mologen AG discuss product pipeline and strategic goals (3/17/03)
- BURGHARDT WITTIG & GUIDO SANDLER, Mologen Holding AG
- Biotechnology

CEO of Maelor Plc discusses product pipeline and opportunities to exploit current products beyond UK market (2/19/03)
- STEPHEN APPELBEE, Maelor PLC
- Pharmaceuticals

CEO of Girindus AG outlines key strengths and objectives in pre-NDA niche (2/19/03)
- FRITZ LINK, Girindus AG
- Pharmaceuticals

Company Interview Excerpt: Jean Archambault - Phytobiotech Inc (1/27/03)
- Jean Archambault, Phytobiotech Inc
- Biotechnology

Analyst has high hopes for Avigen (10/18/02)
- FARIBA F. GHODSIAN, Roth Capital Partners
- Biotechnology

Analyst is encouraged by recent move from AstraZeneca (10/17/02)
- FARIBA F. GHODSIAN, Roth Capital Partners
- Biotechnology

Shire is a winner with analyst (8/30/02)
- DAVID M. STEINBERG, CIBC World Markets
- Pharmaceuticals

Analyst highlights Teva as top pick based on strength of proprietary product (8/28/02)
- MARIA LEGATOS-PHILLIPS, Banc of America Securities
- Pharmaceuticals

Analyst cites Mylan as great long-term buy (8/28/02)
- RODNEY C. SINGL, .W. Henssler & Associates, Ltd.
- Pharmaceuticals

CEO says Fulcrum Pharm PLC aims to increase services and products in Europe, U.S., and Japan (8/26/02)
- JON P. COURT, Fulcrum Pharma PLC
- Pharmaceuticals

CEO of Perbio Science discusses growing market opportunities for protein research tools (8/7/02)
- MATS FISCHIER, Perbio Science AB
- Biotechnology

CFO of Qiagen says clear leadership in tool space is very sustainable (7/31/02)
- PEER M. SCHATZ, Qiagen NV
- Biotechnology

CEO of Compugen outlines opportunities in mergering of drug discovery processes and computational technologies (7/29/02)
- DR. MOR AMITAI, Compugen Ltd.
- Biotechnology

CE of Oxford BioMedica PLC comments on strong and diverse product portfolio (7/24/02)
- PROF ALAN J KINGSMAN, Oxford BioMedica PLC
- Biotechnology

CEO of BioTissue Technologies AG discusses product pipeline and partnership opportunities in tissue (7/17/02)
- DR. VICTOR TIEGERMANN, BioTissue Technologies AG
- Biotechnology

CEO of Genemedix talks about collaboration with the Shanghai Institute of Biochemistry (7/15/02)
- PAUL EDWARDS, GeneMedix plc
- Biotechnology

CEO of MWG BIOTECH discusses turnaround and market potential (7/15/02)
- DR. MATTIAS SCHÖNERMARK, MWG-BIOTECH AG
- Biotechnology

Analyst comments on Millenium's winning hands on formula (7/10/02)
- JONATHAN ASCHOFF, PHD, Friedman, Billings, Ramsey & Co., Inc.
- Biotechnology

Company Interview Excerpt: Gualberto Ruano - Genaissance Pharmaceuticals Inc (GNSC) (7/8/02)
- Gualberto Ruano, Genaissance Pharmaceuticals Inc (GNSC)
- Biotechnology

Analyst favors IDEC Pharmaceuticals (5/24/02)
- ALBERT RAUCH, Ladenburg, Thalmann & Co.
- Biotechnology

ProMetic Life Sciences has very interesting technology, reports Analyst (5/7/02)
- CLAUDE CAMIRÉ, Dundee Securities
- Biotechnology

Company Interview Excerpt: Hans Dieter RÖSSLER - Curasan AG (549453.F) (4/10/02)
- Hans Dieter RÖSSLER, Curasan AG (549453.F)
- Pharmaceuticals

Analyst highlights Johnson & Johnson's rapamycin drug-eluding stent called CYPHER (3/22/02)
- PETER WEN, Credit Suisse Asset Management
- Pharmaceuticals

Analyst highlights Northwest Biotherapeutics (2/20/02)
- FARIBA F. GHODSIAN, Roth Capital Partners
- Biotechnology

Analyst is interested in Nastech (2/7/02)
- LOUIS C. WEBB, RBC Capital Markets
- Drug Delivery

Analyst believes over the next five years, Pfizer will outperform the drug group (12/6/01)
- HEMANT K. SHAH, HKS & Company
- Pharmaceuticals

Analyst explains why he favors GlaxoSmithKline (12/5/01)
- HEMANT K. SHAH, HKS & Company
- Pharmaceuticals

Analyst believes that American Home Products has only a moderately attractive pipeline (12/4/01)
- HEMANT K. SHAH, HKS & Company
- Pharmaceuticals

Company Interview Excerpt: Mark Kirby - Profile Therapeutics - (PTP.L) (10/24/01)
- Mark Kirby, Profile Therapeutics - (PTP.L)
- Drug Delivery

Company Interview Excerpt: Philip Coelho - Thermogenesis Corporation (KOOL) (10/12/01)
- Philip Coelho, Thermogenesis Corporation (KOOL)
- Biotechnology

Company Interview Excerpt: Paul Freiman - Neurobiological Technologies Inc (NTII) (10/12/01)
- Paul Freiman, Neurobiological Technologies Inc (NTII)
- Biotechnology

Analyst has a strong buy on Myriad Genetics on the genomics side (10/10/01)
- RICKY GOLDWASSER, UBS Warburg LLC
- Biotechnology

Analyst cites Genentech as a world-class company (10/5/01)
- MICHAEL G. KING, JR., Robertson Stephens
- Biotechnology

Analyst highlights Collateral Therapeutics' lead product, Generx (10/5/01)
- PETER F. DRAKE, Prudential Securities, Inc.
- Biotechnology

Off The Record: A Premier Biotech Analyst praises Pharmacia's CEO (10/5/01)
- THE WALL STREET TRANSCRIPT, THE WALL STREET TRANSCRIPT CORPORATION
- Biotechnology

Analyst cites MedImmune as a very successful company (10/4/01)
- MICHAEL G. KING, JR., Robertson Stephens
- Biotechnology

Off The Record: Top Industry Watcher cites InterMune as interesting (10/4/01)
- THE WALL STREET TRANSCRIPT, THE WALL STREET TRANSCRIPT CORPORATION
- Biotechnology

Analyst highlights Amgen's product, Aranesp (10/4/01)
- MICHAEL G. KING, JR., Robertson Stephens
- Biotechnology

Off The Record: Human Genome Science’s management is doing it quite right, a Biotech Expert reports (10/3/01)
- THE WALL STREET TRANSCRIPT, THE WALL STREET TRANSCRIPT CORPORATION
- Biotechnology

Analyst rates ICOS as a buy-rated stock (10/3/01)
- PETER F. DRAKE, Prudential Securities, Inc.
- Biotechnology

Analyst highlights Serono (10/2/01)
- PETER F. DRAKE, Prudential Securities, Inc.
- Biotechnology

Company Interview Excerpt: Paul Clark - Icos Corporation (ICOS) (9/14/01)
- Paul Clark, Icos Corporation (ICOS)
- Biotechnology

Company Interview Excerpt: Axel Unterbeck - Memory Pharmaceuticals Corporation (9/14/01)
- Axel Unterbeck, Memory Pharmaceuticals Corporation
- Pharmaceuticals

Analyst expects to see acceleration in development activity around both of Alkermes' technologies (6/7/01)
- IAN SANDERSON, SG Cowen
- Drugs - Generic

Analyst states Enzon is an accelerating earnings growth story (6/6/01)
- IAN SANDERSON, SG Cowen
- Drugs - Generic

Analyst comments on Allergan (6/5/01)
- IAN SANDERSON, SG Cowen
- Drugs - Generic

Company Interview Excerpt: Joseph Rubinfeld - Supergen, Inc. (SUPG) (5/22/01)
- Joseph Rubinfeld, Supergen, Inc. (SUPG)
- Biotechnology

CEO comments on Caliper Technologies' first product line, Personal Laboratory System (5/10/01)
- DR. DANIEL L. KISNER, Caliper Technologies Corp.
- Biotechnology

CEO of Visible Genetics talks about the size potential of marketplace (5/8/01)
- RICHARD T. DALY, Visible Genetics Inc.
- Biotechnology

Analyst says Affymetrix is the leader in the micro-array marketplace (4/12/01)
- GEOFFREY HARRIS, UBS Warburg
- Biotechnology

Analyst explains why Tularik is a strong buy (3/30/01)
- CHARLES C. DUNCAN, Prudential Securities
- Biotechnology

Analyst highlights Myriad Genetics' products (3/29/01)
- CHARLES C. DUNCAN, Prudential Securities
- Biotechnology

CFO talks about the tremendous opportunity for Hollis-Eden Pharmaceuticals (2/27/01)
- DANIEL D. BURGESS, Hollis-Eden Pharmaceuticals, Inc.
- Pharmaceuticals

Off The Record: Top Analyst comments on Aviron's new flu vaccine (1/26/01)
- THE WALL STREET TRANSCRIPT, THE WALL STREET TRANSCRIPT CORPORATION
- Pharmaceuticals

CEO outlines reasons for investing in Bentley Pharmaceuticals (1/26/01)
- JAMES R. MURPHY, Bentley Pharmaceuticals, Inc.
- Biotechnology

ING Barings' Analyst believes Merck will continue to do well (1/25/01)
- SERGIO C. TRAVERSA, ING Barings, L.L.C.
- Pharmaceuticals

Analyst calls Immunomedics a home run bid (1/25/01)
- D. LARRY SMITH, Sutro and Company
- Pharmaceuticals

CEO comments on Gene Logic's financial situation (1/12/01)
- MARK GESSLER, Gene Logic, Inc.
- Biotechnology

Genzyme's CEO believes that Renagel will be the growth driver for the company in the next few years (1/12/01)
- HENRI TERMEER, Genzyme Corporation
- Biotechnology

CEO explains how Gemini Genomics differentiates itself from other people who are doing parallel things (1/12/01)
- DR. PAUL KELLY, Gemini Genomics Plc
- Biotechnology

CEO reports on Genaissance Pharmaceuticals' partnership with Janssen Research Foundation (1/12/01)
- DR. GUALBERTO RUAÑO, Genaissance Pharmaceuticals, Inc.
- Biotechnology

Senior Vice President explains HCA—The Healthcare Company's “patients first” philosophy (1/12/01)
- VICTOR L. CAMPBELL, HCA—The Healthcare Company
- Biotechnology

CEO outlines Pharsight's plans for potential partnerships (1/12/01)
- ARTHUR H. REIDEL, Pharsight Corp.
- Pharmaceuticals

President talks about the benchmarks investors should use to judge Genzyme Biosurgery's progress (1/12/01)
- EARL M. "DUKE" COLLIER, JR., Genzyme Biosurgery
- Biotechnology

Senior Vice President reports on Inspire Pharmaceuticals' hybrid strategy regarding the commercialization of its technology (1/12/01)
- GREGORY J. MOSSINGHOFF, Inspire Pharmaceuticals, Inc.
- Biotechnology

CEO reports on Human Genome Sciences' competitive edge (1/12/01)
- DR. WILLIAM A. HASELTINE, Human Genome Sciences, Inc.
- Biotechnology

President is proud of Caremark Rx' financial ratios (1/11/01)
- JAMES H. DICKERSON, JR., Caremark Rx, Inc.
- Pharmaceuticals

CEO looks at the competition for MedQuist (1/11/01)
- JOHN A. DONOHOE, MedQuist Inc.
- Pharmaceuticals

CEO believes that Molecular Devices can continue to expand its lead in providing innovative technology for drug discovery research (1/11/01)
- JOSEPH D. KEEGAN, Molecular Devices Corp.
- Biotechnology

Matrix Pharmaceutical's CEO is very excited about the commercial potential of IntraDose (1/11/01)
- MICHAEL CASEY, Matrix Pharmaceutical, Inc.
- Pharmaceuticals

CEO comments on Amylin Pharmaceuticals' top management team (1/11/01)
- JOSEPH COOK, JR., Amylin Pharmaceuticals, Inc.
- Pharmaceuticals

CEO reports on the significant advantages of SangStat Medical's RDP58 over existing TNF-alpha inhibitors (1/11/01)
- JEAN-JACQUES BIENAIMÉ, SangStat Medical Corp.
- Biotechnology

CEO looks at the competitive advantages for DIANON Systems (1/11/01)
- KEVIN C. JOHNSON, DIANON Systems, Inc.
- Diagnostic Substances

CEO outlines the competitive environment for Esperion Therapeutics (1/11/01)
- ROGER NEWTON, Esperion Therapeutics, Inc.
- Drugs - Generic

CollaGenex Pharmaceuticals' CEO reports on the market size for a product like Periostat (1/11/01)
- BRIAN M. GALLAGHER, CollaGenex Pharmaceuticals, Inc.
- Pharmaceuticals

Pharsight will focus on establishing its information products business, reports CEO (1/11/01)
- ARTHUR H. REIDEL, Pharsight Corp.
- Pharmaceuticals

CEO reports on the management team at Versicos (1/11/01)
- GEORGE F. HORNER, III, Versicos, Inc.
- Biotechnology

Medarex will continue to look for opportunities to acquire complementary technologies, reports CEO (1/11/01)
- DONALD L. DRAKEMAN, Medarex, Inc.
- Biotechnology

3-Dimensional Pharmaceuticals' strategy is to license out whatever the company develops, states CEO (1/11/01)
- DAVID C. U’PRICHARD, 3-Dimensional Pharmaceuticals, Inc.
- Biotechnology

Valentis' goal is to continue to have the broadest array of delivery technologies for biopharmaceuticals in the industry, reports (1/11/01)
- BENJAMIN F. MCGRAW III, Valentis, Inc.
- Biotechnology

Tularik's goal is to submit one to two IND applications per year, reports CEO (1/11/01)
- ANDREW J. PERLMAN, Tularik, Inc.
- Biotechnology

CEO comments on Biogen's current stock price (1/11/01)
- JAMES C. MULLEN, Biogen, Inc.
- Biotechnology

CEO outlines QIAGEN's sales and marketing strategies (1/11/01)
- DR. METIN COLPAN, QIAGEN
- Biotechnology

CEO reports on Celgene's objective to build a major integrated pharmaceutical company focused on cancer and immunology (1/11/01)
- JOHN W. JACKSON, Celgene Corporation
- Biotechnology

CEO points to the single best opportunity in the near future for First Horizon Pharmaceutical (1/11/01)
- MAHENDRA G. SHAH, First Horizon Pharmaceutical Corporation
- Pharmaceuticals

CEO comments on the competitive landscape for SpectRx (1/11/01)
- MARK SAMUELS, SpectRx, Inc.
- Biotechnology

CEO of Medicis Pharmaceutical speaks about the trends in cosmetic dermatology (1/11/01)
- Medicis Pharmaceutical Corp., Medicis Pharmaceutical Corp
- Pharmaceuticals

Partnering continues to be a very important part of NPS Pharmaceuticals' strategy, reports CEO (1/11/01)
- HUNTER JACKSON, NPS Pharmaceuticals, Inc.
- Biotechnology

CEO of Albany Molecular Research believes that there is an increased need to outsource in pharma R&D (1/11/01)
- DR. THOMAS E. D’AMBRA, Albany Molecular Research, Inc.
- Biotechnology

CEO reports on DURECT's lead product: DUROS sufentanil (1/11/01)
- JAMES BROWN, DURECT Corp.
- Drug Related Products

CEO explains why AtheroGenics' R&D expenditures for the next year may increase (1/11/01)
- RUSSELL M. MEDFORD, AtheroGenics, Inc.
- Biotechnology

CEO looks at the competition for Angiotech Pharmaceuticals (1/11/01)
- WILLIAM L. HUNTER, Angiotech Pharmaceuticals, Inc.
- Pharmaceuticals

CEO praises Vertex Pharmaceuticals' scientific and business team (1/11/01)
- DR. JOSHUA BOGER, Vertex Pharmaceuticals, Inc.
- Pharmaceuticals



For more information call (212) 952 7400. The Wall Street Transcript does not endorse any of the comments made by interviewees, and does not make stock recommendations.

Copyright 1999, Wall Street Transcript Corp.